Long term outcomes of phase III KEEPsAKE 2 trial in #PsA; SC risankizumab 150 mg given q12wks (after wk 24). 78% were ongoing. RZK achieved 60% ACR20 at wk 52, 57% ACR20 at wk 100, & 75% maintained ACR20 to wk 100. MDA achieved in 34% & 33%.https://t.co/juYQklrhG3 https://t.co/8uhmydPZDf